Healthcare Press

Semaglutide Aids Weight Loss in Those With IBD and Obesity

  • 📰 Medscape
  • ⏱ Reading Time:
  • 35 sec. here
  • 25 min. at publisher
  • 📊 Quality Score:
  • News: 97%
  • Publisher: 55%

Obesity News

Obese,Weight Loss,Inflammatory Bowel Disease

Semaglutide was equally effective for obesity in patients with or without IBD, with a more than 5% mean weight loss and no increased risk for disease-specific adverse events.

as in those without IBD and greater weight loss than other anti-obesity medications except tirzepatide, with no increase in IBD-specific adverse events.Although semaglutide has shown significant and sustained weight loss in the general population, its efficacy for obesity treatment in patients with IBD remains unexplored.

This retrospective cohort study utilized data from TriNetX, a US multi-institutional database, to compare patients with obesity and IBD and those without IBD . Propensity score matching was used to match 150 patients with obesity and IBD who were prescribed semaglutide to an equal number of patients without IBD .

The IBD cohort was followed up for 18 months, while the non-IBD cohort was followed up for 19.4 months post semaglutide initiation. The primary objective was to assess semaglutide's effectiveness in the IBD and non-IBD cohorts. Efficacy was defined as total body weight changes from baseline to between 6 and 15 months from the initiation of semaglutide.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 386. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Beyond Weight Loss: Semaglutide Delivers Major Heart Health BenefitsScience, Space and Technology News 2024
Source: SciTechDaily1 - 🏆 84. / 68 Read more »

Ozempic Drug Semaglutide Could Cut Heart Risk By 20%—Regardless Of Weight Loss, Study FindsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Source: ForbesTech - 🏆 318. / 59 Read more »

Ozempic Drug Semaglutide Could Cut Heart Risk By 20%—Regardless Of Weight Loss, Study FindsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Source: Forbes - 🏆 394. / 53 Read more »